Mainz Biomed Regains Nasdaq Compliance

Mainz Biomed N.V., a company specializing in molecular genetic diagnostics for early cancer detection, has announced its renewed compliance with Nasdaq Capital Market listing requirements. The confirmation from Nasdaq was received on January 23, 2025. This update confirms Mainz Biomed’s adherence to the minimum stockholders' equity and bid price requirements, ensuring its continued presence on the Nasdaq Capital Market.

Based in Berkeley, US, and Mainz, Germany, Mainz Biomed continues to focus on its flagship ColoAlert®, a colorectal cancer diagnostic test marketed in Europe and the UAE. The company is pursuing FDA approval in the U.S., with a focus on innovation in early-stage cancer detection solutions such as PancAlert.